Please Wait.....
Report
Insulin Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034
Market Report I 2025-02-18 I 148 Pages I Global Market Insights
The Global Insulin Market was valued at USD 29.4 billion in 2024 and is projected to grow at a CAGR of 3.7% from 2025 to 2034. The increasing prevalence of diabetes, especially type 2, is driving market expansion. Factors such as a sedentary lifestyle, rising obesity rates, and an aging population significantly contribute to this growth. Other risk factors, including high-calorie diets, genetic predisposition, and stress, also play a crucial role in diabetes prevalence.
Growing awareness and early medical interventions have increased the demand for insulin therapy, which remains essential for diabetes management. Advances in insulin formulations, including ultra-rapid-acting, long-acting, and biosimilar insulins, have improved treatment adherence and patient outcomes. Additionally, increased government and NGO investments in developing regions have expanded insulin access, further strengthening the market. Favorable reimbursement policies in developed economies have also contributed to market expansion.
Insulin is essential in regulating blood glucose levels, ensuring efficient energy utilization. The market includes various insulin formulations, including rapid-acting, short-acting, intermediate-acting, long-acting, and premixed options, as well as biosimilars.
The market is segmented into human insulin and insulin analogs. Insulin analogs dominated the market, accounting for USD 22.3 billion in 2024. Their widespread adoption stems from superior efficacy, lower risk of hypoglycemia, and better patient adherence compared to traditional human insulin. Insulin analogs provide greater dosing flexibility, reduce postprandial glucose spikes, and offer a more predictable response. Long-acting insulin analogs, such as insulin detemir, also minimize weight gain compared to regular insulin. The availability of biosimilar insulin analogs has further expanded accessibility and affordability.
By product type, the market is divided into long-acting insulin, rapid-acting insulin, combination insulin, biosimilars, and other products. Long-acting insulin held the largest share at 45.4% in 2024. Its slow-release mechanism ensures stable insulin levels, reducing the frequency of injections and enhancing patient adherence. These formulations effectively mimic basal insulin secretion, lowering the risk of hypoglycemia. The development of advanced long-acting insulin products and improvements in insulin delivery devices continue to support market dominance.
The market is categorized by application into type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 1 diabetes accounted for 75.2% of the market in 2024 and is expected to grow at a CAGR of 3.6%. Patients with type 1 diabetes rely on daily insulin injections to maintain blood glucose levels. Unlike type 2 diabetes, where lifestyle modifications and oral medications may be effective, type 1 diabetes necessitates consistent insulin administration.
In terms of distribution channels, hospital pharmacies led the market in 2024, projected to reach USD 22.4 billion by 2034. High diabetes-related hospital admissions, access to a wide range of insulin products, and advanced healthcare systems contribute to this segment's dominance.
Regionally, North America led the market with a 40.3% share in 2023. The US market grew from USD 9.6 billion in 2022 to USD 10.2 billion in 2023. The country's high diabetes prevalence, robust healthcare infrastructure, and strong investments in insulin research and development continue to drive market growth. The presence of leading insulin manufacturers further supports market expansion.
Report Content
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of diabetes
3.2.1.2 Advancements in insulin delivery systems
3.2.1.3 Government initiatives and policies
3.2.1.4 Focus on pediatric diabetes
3.2.2 Industry pitfalls and challenges
3.2.2.1 High cost of insulin
3.2.2.2 Availability of alternative therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Diabetes landscape
3.6.1 Number of diabetics worldwide, by region, 2023
3.6.2 Countries with the highest number of diabetics, 2023
3.6.3 Number of diabetes deaths worldwide, by region, 2023
3.6.4 Countries with the highest projected number of diabetics worldwide in 2045
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)
5.1 Key trends
5.2 Human insulin
5.3 Insulin analog
Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)
6.1 Key trends
6.2 Rapid-acting insulin
6.3 Long-acting insulin
6.4 Combination insulin
6.5 Biosimilar
6.6 Other products
Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
7.1 Key trends
7.2 Type 1 diabetes mellitus
7.3 Type 2 diabetes mellitus
7.4 Gestational diabetes
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Netherlands
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Adocia
10.2 Biocon
10.3 Boehringer Ingelheim International
10.4 Eli Lilly and Company
10.5 Gan & Lee Pharmaceuticals
10.6 Gland Pharma
10.7 Julphar
10.8 MannKind Corporation
10.9 Novo Nordisk
10.10 Pfizer
10.11 Sanofi
10.12 Shanghai Fosun Pharmaceutical
10.13 Tonghua Dongbao Pharmaceutical
10.14 United Laboratories International
10.15 Wockhardt
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security